Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Acquires 831 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 831 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was bought at an average cost of $23.34 per share, with a total value of $19,395.54. Following the transaction, the chief financial officer directly owned 33,885 shares of the company’s stock, valued at approximately $790,875.90. This trade represents a 2.51% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Sensei Biotherapeutics Stock Down 5.4%

FTH stock opened at $23.66 on Thursday. The stock has a market capitalization of $31.70 million, a PE ratio of -0.17 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. Equities analysts predict that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on FTH shares. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Robert W. Baird started coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. Finally, HC Wainwright assumed coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.